These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37028871)

  • 1. Elucidating the role of N-acetylglucosamine in Group A Carbohydrate for the development of an effective glycoconjugate vaccine against Group A Streptococcus.
    Pitirollo O; Di Benedetto R; Henriques P; Gasperini G; Mancini F; Carducci M; Massai L; Rossi O; Volbeda AG; Codée JDC; Berlanda Scorza F; Moriel DG; Necchi F; Lay L; Adamo R; Micoli F
    Carbohydr Polym; 2023 Jul; 311():120736. PubMed ID: 37028871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The molecular mechanism of
    Rush JS; Edgar RJ; Deng P; Chen J; Zhu H; van Sorge NM; Morris AJ; Korotkov KV; Korotkova N
    J Biol Chem; 2017 Nov; 292(47):19441-19457. PubMed ID: 29021255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virulence Role of the GlcNAc Side Chain of the Lancefield Cell Wall Carbohydrate Antigen in Non-M1-Serotype Group A
    Henningham A; Davies MR; Uchiyama S; van Sorge NM; Lund S; Chen KT; Walker MJ; Cole JN; Nizet V
    mBio; 2018 Jan; 9(1):. PubMed ID: 29382733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GMMA as an Alternative Carrier for a Glycoconjugate Vaccine against Group A
    Palmieri E; Kis Z; Ozanne J; Di Benedetto R; Ricchetti B; Massai L; Carducci M; Oldrini D; Gasperini G; Aruta MG; Rossi O; Kontoravdi C; Shah N; Mawas F; Micoli F
    Vaccines (Basel); 2022 Jun; 10(7):. PubMed ID: 35891202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The classical lancefield antigen of group a Streptococcus is a virulence determinant with implications for vaccine design.
    van Sorge NM; Cole JN; Kuipers K; Henningham A; Aziz RK; Kasirer-Friede A; Lin L; Berends ETM; Davies MR; Dougan G; Zhang F; Dahesh S; Shaw L; Gin J; Cunningham M; Merriman JA; Hütter J; Lepenies B; Rooijakkers SHM; Malley R; Walker MJ; Shattil SJ; Schlievert PM; Choudhury B; Nizet V
    Cell Host Microbe; 2014 Jun; 15(6):729-740. PubMed ID: 24922575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational Design of a Glycoconjugate Vaccine against Group A
    Di Benedetto R; Mancini F; Carducci M; Gasperini G; Moriel DG; Saul A; Necchi F; Rappuoli R; Micoli F
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress towards a glycoconjugate vaccine against Group A Streptococcus.
    Burns K; Dorfmueller HC; Wren BW; Mawas F; Shaw HA
    NPJ Vaccines; 2023 Mar; 8(1):48. PubMed ID: 36977677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunobiology of the Classical Lancefield Group A Streptococcal Carbohydrate Antigen.
    Gao NJ; Rodas Lima E; Nizet V
    Infect Immun; 2021 Nov; 89(12):e0029221. PubMed ID: 34543125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fc region-dependence of IgG3 anti-streptococcal group A carbohydrate antibody functional affinity. I. The effect of temperature.
    Greenspan NS; Dacek DA; Cooper LJ
    J Immunol; 1988 Dec; 141(12):4276-82. PubMed ID: 3058803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Group A, B, C, and G
    Zorzoli A; Meyer BH; Adair E; Torgov VI; Veselovsky VV; Danilov LL; Uhrin D; Dorfmueller HC
    J Biol Chem; 2019 Oct; 294(42):15237-15256. PubMed ID: 31506299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity Assessment of Cell Wall Carbohydrates of Group A
    Khatun F; Dai CC; Rivera-Hernandez T; Hussein WM; Khalil ZG; Capon RJ; Toth I; Stephenson RJ
    ACS Infect Dis; 2021 Feb; 7(2):390-405. PubMed ID: 33533246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering a suite of E. coli strains for enhanced expression of bacterial polysaccharides and glycoconjugate vaccines.
    Kay EJ; Mauri M; Willcocks SJ; Scott TA; Cuccui J; Wren BW
    Microb Cell Fact; 2022 Apr; 21(1):66. PubMed ID: 35449016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Group A
    Wang S; Zhao Y; Wang G; Feng S; Guo Z; Gu G
    ACS Infect Dis; 2020 Feb; 6(2):281-290. PubMed ID: 31872763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a Group A Streptococcus synthetic oligosaccharide as vaccine candidate.
    Kabanova A; Margarit I; Berti F; Romano MR; Grandi G; Bensi G; Chiarot E; Proietti D; Swennen E; Cappelletti E; Fontani P; Casini D; Adamo R; Pinto V; Skibinski D; Capo S; Buffi G; Gallotta M; Christ WJ; Campbell AS; Pena J; Seeberger PH; Rappuoli R; Costantino P
    Vaccine; 2010 Dec; 29(1):104-14. PubMed ID: 20870056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular basis for recognition of the Group A Carbohydrate backbone by the PlyC streptococcal bacteriophage endolysin.
    King H; Ajay Castro S; Pohane AA; Scholte CM; Fischetti VA; Korotkova N; Nelson DC; Dorfmueller HC
    Biochem J; 2021 Jun; 478(12):2385-2397. PubMed ID: 34096588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunochemical analysis of streptococcal group A, B, and C carbohydrates, with emphasis on group A.
    Fung JC; Wicher K; McCarty M
    Infect Immun; 1982 Jul; 37(1):209-15. PubMed ID: 7049950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo production of a novel glycoconjugate vaccine against Shigella flexneri 2a in recombinant Escherichia coli: identification of stimulating factors for in vivo glycosylation.
    Kämpf MM; Braun M; Sirena D; Ihssen J; Thöny-Meyer L; Ren Q
    Microb Cell Fact; 2015 Jan; 14():12. PubMed ID: 25612741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of IgG3 anti-streptococcal group A carbohydrate (GAC) antibody with streptococcal group A vaccine: enhancing and inhibiting effects of anti-GAC, anti-isotypic, and anti-idiotypic antibodies.
    Greenspan NS; Monafo WJ; Davie JM
    J Immunol; 1987 Jan; 138(1):285-92. PubMed ID: 2431057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Poly-N-acetylglucosamine-Shiga toxin broad-spectrum conjugate vaccine for Shiga toxin-producing Escherichia coli.
    Lu X; Skurnik D; Pozzi C; Roux D; Cywes-Bentley C; Ritchie JM; Munera D; Gening ML; Tsvetkov YE; Nifantiev NE; Waldor MK; Pier GB
    mBio; 2014 Mar; 5(2):e00974-14. PubMed ID: 24667709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Semisynthetic glycoconjugate vaccine candidate against
    Lisboa MP; Khan N; Martin C; Xu FF; Reppe K; Geissner A; Govindan S; Witzenrath M; Pereira CL; Seeberger PH
    Proc Natl Acad Sci U S A; 2017 Oct; 114(42):11063-11068. PubMed ID: 28973947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.